Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2002 7
2003 8
2004 10
2005 5
2006 8
2007 12
2008 14
2009 6
2010 10
2011 8
2012 13
2013 12
2014 9
2015 8
2016 11
2017 11
2018 7
2019 8
2020 10
2021 15
2022 11
2023 5
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Results by year

Filters applied: . Clear all
Page 1
Mycosis Fungoides and Sezary Syndrome: Updates and Review of Current Therapy.
Kamijo H, Miyagaki T. Kamijo H, et al. Curr Treat Options Oncol. 2021 Jan 7;22(2):10. doi: 10.1007/s11864-020-00809-w. Curr Treat Options Oncol. 2021. PMID: 33415447 Review.
While most patients with early-stage mycosis fungoides (MF) follow an indolent course, patients with advanced-stage MF/Sezary syndrome (SS) have a poor prognosis with a median survival of less than 5 years. ...For advanced-stage MF/SS, systemic treatments by biologi …
While most patients with early-stage mycosis fungoides (MF) follow an indolent course, patients with advanced-stage MF/Sezary …
The utility of bexarotene in mycosis fungoides and Sezary syndrome.
Panchal MR, Scarisbrick JJ. Panchal MR, et al. Onco Targets Ther. 2015 Feb 3;8:367-73. doi: 10.2147/OTT.S61308. eCollection 2015. Onco Targets Ther. 2015. PMID: 25678803 Free PMC article. Review.
Cutaneous T-cell lymphoma (CTCL) is an umbrella term that encompasses a group of neoplasms that have atypical T-lymphocytes in the skin. Mycosis fungoides (MF) is the most common type of CTCL and Sezary syndrome (SS) is the leukemic form. ...We review the use of …
Cutaneous T-cell lymphoma (CTCL) is an umbrella term that encompasses a group of neoplasms that have atypical T-lymphocytes in the skin. …
Treatment of early-stage mycosis fungoides with oral bexarotene and phototherapy: A systematic review and meta-analysis.
Ginsburg E, Hennessy K, Mhaskar R, Seminario-Vidal L. Ginsburg E, et al. Dermatol Ther. 2022 May;35(5):e15418. doi: 10.1111/dth.15418. Epub 2022 Mar 16. Dermatol Ther. 2022. PMID: 35243730
Mycosis fungoides (MF) is a rare subtype of non-Hodgkin lymphoma, for which no standard treatment exists. The objective of this study is to provide evidence-based recommendations for adult patients with early-stage MF treated with oral bexarotene and photothe …
Mycosis fungoides (MF) is a rare subtype of non-Hodgkin lymphoma, for which no standard treatment exists. The objective of thi …
Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides.
Vitiello P, Sagnelli C, Ronchi A, Franco R, Caccavale S, Mottola M, Pastore F, Argenziano G, Creta M, Calogero A, Fiorelli A, Casale B, Sica A. Vitiello P, et al. Healthcare (Basel). 2023 Feb 18;11(4):614. doi: 10.3390/healthcare11040614. Healthcare (Basel). 2023. PMID: 36833148 Free PMC article. Review.
Mycosis fungoides's classic type typically onsets with cutaneous erythematous patches, plaque, and tumor. In WHO-EORTC classification, folliculotropic mycosis fungoides, pagetoid reticulosis, and granulomatous slack skin are recognized as distinct vari …
Mycosis fungoides's classic type typically onsets with cutaneous erythematous patches, plaque, and tumor. In WHO-EORTC classif …
Phototherapy for mycosis fungoides.
Dogra S, Mahajan R. Dogra S, et al. Indian J Dermatol Venereol Leprol. 2015 Mar-Apr;81(2):124-35. doi: 10.4103/0378-6323.152169. Indian J Dermatol Venereol Leprol. 2015. PMID: 25751327 Free article. Review.
BACKGROUND: Both phototherapy and photochemotherapy have been used in all stages of mycosis fungoides since they improve the symptoms and have a favourable adverse effect profile. ...CONCLUSIONS AND RECOMMENDATIONS: Photochemotherapy in the form of psoralens with ul …
BACKGROUND: Both phototherapy and photochemotherapy have been used in all stages of mycosis fungoides since they improve the s …
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Horwitz SM, et al. Blood Adv. 2021 Dec 14;5(23):5098-5106. doi: 10.1182/bloodadvances.2021004710. Blood Adv. 2021. PMID: 34507350 Free PMC article. Clinical Trial.
The primary analysis of the phase 3 ALCANZA trial showed significantly improved objective responses lasting 4 months (ORR4; primary endpoint) and progression-free survival (PFS) with brentuximab vedotin vs physician's choice (methotrexate or bexarotene) in CD30-expressing …
The primary analysis of the phase 3 ALCANZA trial showed significantly improved objective responses lasting 4 months (ORR4; primary endpoint …
GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.
Booth MR, Booth L, Roberts JL, West C, Dent P. Booth MR, et al. Oncotarget. 2024 Feb 8;15:124-133. doi: 10.18632/oncotarget.28557. Oncotarget. 2024. PMID: 38329728 Free PMC article.
The biology of GZ17-6.02 in malignant T cells and in particular those derived from mycosis fungoides (MF) patients, has not been studied. GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells. ...
The biology of GZ17-6.02 in malignant T cells and in particular those derived from mycosis fungoides (MF) patients, has not be …
Bexarotene therapy for mycosis fungoides and Sezary syndrome.
Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ. Abbott RA, et al. Br J Dermatol. 2009 Jun;160(6):1299-307. doi: 10.1111/j.1365-2133.2009.09037.x. Epub 2009 Feb 16. Br J Dermatol. 2009. PMID: 19222457
METHODS: A retrospective study of 66 patients (44 male, 22 female) with mycosis fungoides (40 patients) or Sezary syndrome (26 patients) who were commenced on bexarotene prior to August 2007 was carried out. Nineteen patients had early-stage (IB-IIA) refracto …
METHODS: A retrospective study of 66 patients (44 male, 22 female) with mycosis fungoides (40 patients) or Sezary syndrome (26 …
197 results